Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection.

Omicron SARS-CoV-2 breakthrough infection neutralization vaccination

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 17 03 2022
accepted: 05 05 2022
entrez: 12 7 2022
pubmed: 13 7 2022
medline: 13 7 2022
Statut: epublish

Résumé

The emergence of severe acute respiratory syndrome coronavirus 2 variants that have greater transmissibility and resistance to neutralizing antibodies has increased the incidence of breakthrough infections. We show that breakthrough infection increases neutralizing antibody titers to varying degrees depending on the nature of the breakthrough variant and the number of vaccine doses previously administered. Omicron breakthrough infection resulted in neutralizing antibody titers that were the highest across all groups, particularly against Omicron.

Identifiants

pubmed: 35818364
doi: 10.1093/ofid/ofac227
pii: ofac227
pmc: PMC9129198
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofac227

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI078788
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI111825
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001866
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

Nat Med. 2022 Mar;28(3):477-480
pubmed: 35046572
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Lancet. 2022 Feb 12;399(10325):625-626
pubmed: 35063123
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Nature. 2021 Dec;600(7889):512-516
pubmed: 34544114
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165

Auteurs

Christian Gaebler (C)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Justin DaSilva (J)

Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA.

Eva Bednarski (E)

Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA.

Frauke Muecksch (F)

Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA.

Fabian Schmidt (F)

Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA.

Yiska Weisblum (Y)

Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA.

Katrina G Millard (KG)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Martina Turroja (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Alice Cho (A)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Zijun Wang (Z)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Marina Caskey (M)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Michel C Nussenzweig (MC)

Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.

Paul D Bieniasz (PD)

Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA.

Theodora Hatziioannou (T)

Laboratory of Retrovirology, The Rockefeller University, New York, New York, USA.

Classifications MeSH